UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.e637-e646

2024

Volltextzugriff (PDF)

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

The Journal of infectious diseases, 2017-12, Vol.216 (11), p.1362-1370

2017

Volltextzugriff (PDF)

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.e647-e656

2024

Volltextzugriff (PDF)

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

The Lancet infectious diseases, 2016-08, Vol.16 (8), p.e153-e163

2016

Volltextzugriff (PDF)

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Clinical infectious diseases, 2024-05, Vol.78 (5), p.1360-1368

2024

Volltextzugriff (PDF)

Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial

The Journal of infectious diseases, 2024-08, Vol.230 (2), p.e374-e383

2024

Volltextzugriff (PDF)

Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination

The Journal of infectious diseases, 2024-10, Vol.230 (4), p.e905-e916

2024

Volltextzugriff (PDF)

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

The Journal of infectious diseases, 2020-02, Vol.221 (4), p.534-543

2020

Volltextzugriff (PDF)

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

The Journal of infectious diseases, 2017-01, Vol.215 (1), p.24-33

2017

Volltextzugriff (PDF)

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

The Journal of infectious diseases, 2024-07, Vol.230 (1), p.e102-e110

2024

Volltextzugriff (PDF)

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Clinical infectious diseases, 2024-10, Vol.79 (4), p.1088-1098

2024

Volltextzugriff (PDF)

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

Clinical infectious diseases, 2024-08, Vol.79 (4), p.1074-1084

2024

Volltextzugriff (PDF)

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study

The Journal of infectious diseases, 2024-08, Vol.230 (2), p.e353-e362

2024

Volltextzugriff (PDF)

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults

The Journal of infection, 2024-08, Vol.89 (2), p.106211, Article 106211

2024

Volltextzugriff (PDF)

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

The Journal of infectious diseases, 2018-04, Vol.217 (10), p.1616-1625

2018

Volltextzugriff (PDF)

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

Clinical and vaccine immunology, 2017-09, Vol.24 (9)

2017

Volltextzugriff (PDF)

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

The Lancet infectious diseases, 2015-12, Vol.15 (12), p.1398-1408

2015

Volltextzugriff (PDF)

Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?

Current opinion in infectious diseases, 2015-06, Vol.28 (3), p.221-224

Munoz, Flor M

2015

Volltextzugriff (PDF)

Potential impact of a maternal vaccine for RSV: A mathematical modelling study

Vaccine, 2017-10, Vol.35 (45), p.6172-6179

2017

Volltextzugriff (PDF)

Respiratory Syncytial Virus Load, Viral Dynamics, and Disease Severity in Previously Healthy Naturally Infected Children

The Journal of infectious diseases, 2011-10, Vol.204 (7), p.996-1002

2011

Volltextzugriff (PDF)

Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection

PLoS pathogens, 2018-01, Vol.14 (1), p.e1006810-e1006810

2018

Volltextzugriff (PDF)

Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses

The Journal of infectious diseases, 2007-04, Vol.195 (8), p.1126-1136

2007

Volltextzugriff (PDF)

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats

Vaccine, 2013-04, Vol.31 (17), p.2169-2176

2013

Volltextzugriff (PDF)

Passive Immunization Strategies to Prevent Severe Respiratory Syncytial Virus Infection Among Newborns and Young Infants

Journal of the Pediatric Infectious Diseases Society, 2024-07, Vol.13 (Supplement_2), p.S110-S114

Suryadevara, Manika

2024

Volltextzugriff (PDF)

Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins

Antiviral research, 2014-11, Vol.111, p.129-135

2014

Volltextzugriff (PDF)

1 – 25 von 933

Suche als RSS-Feed

Aktive Filter

ThemaFemale

ThemaInfectious Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(924)
Mit Volltextzugriff
(624)

Publikationsform

Artikel
(933)

Sprache

Englisch
(931)
Spanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(912)
Life Sciences & Biomedicine
(880)
Humans
(848)
Male
(766)
Immunology
(701)
Respiratory Syncytial Virus
(660)
Infant
(572)
Biological And Medical Sciences
(494)
Medical Sciences
(480)
Microbiology
(393)
Viral Diseases
(386)
Pediatrics
(349)
Human Viral Diseases
(336)
Child, Preschool
(332)
Infant, Newborn
(299)
Viral Diseases Of The Respiratory System And Ent Viral Diseases
(289)
Viruses
(243)
Respiratory Syncytial Virus Infections - Epidemiology
(228)

13 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial

Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?

Potential impact of a maternal vaccine for RSV: A mathematical modelling study

Respiratory Syncytial Virus Load, Viral Dynamics, and Disease Severity in Previously Healthy Naturally Infected Children

Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection

Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats

Passive Immunization Strategies to Prevent Severe Respiratory Syncytial Virus Infection Among Newborns and Young Infants

Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins

Aktive Filter

Suchergebnisse filtern